Leerink raised the firm’s price target on Cogent Biosciences (COGT) to $18 from $16 and keeps an Outperform rating on the share after the company reported topline results from SUMMIT Part 2, the pivotal trial of bezuclastinib in indolent systemic mastocytosis. While the efficacy on a placebo-adjusted rate was in line with the firm’s expectations, safety was better than anticipated, positioning the stock well for the APEX and PEAK readouts in the second half of 2025 and year-end 2025, respectively.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences price target raised at Jefferies after ‘home run’ data
- Cogent Biosciences trading resumes
- Cogent Biosciences trading halted, volatility trading pause
- Morning Movers: WNS Holdings jumps following deal to be bought by Capgemini
- Cogent Biosciences Announces Positive SUMMIT Trial Results